novartis pharma - Robuta Search

https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions?page=1&q%5Bs%5D=id+asc AIcrowd | Novartis Pharma Data Science Hackathon | Submissions data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon AIcrowd | Novartis Pharma Data Science Hackathon | Challenges data science hackathon novartis pharma aicrowd challenges https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions?page=1&q%5Bs%5D=score_secondary_display+desc AIcrowd | Novartis Pharma Data Science Hackathon | Submissions data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions/14594 AIcrowd | Novartis Pharma Data Science Hackathon | Submissions #14594 data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions?page=1&q%5Bs%5D=name+desc AIcrowd | Novartis Pharma Data Science Hackathon | Submissions data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions?baselines=false AIcrowd | Novartis Pharma Data Science Hackathon | Submissions data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions/15771 AIcrowd | Novartis Pharma Data Science Hackathon | Submissions #15771 data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions/15763 AIcrowd | Novartis Pharma Data Science Hackathon | Submissions #15763 data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions?baselines=true&page=1&q%5Bs%5D=score_secondary_display+asc AIcrowd | Novartis Pharma Data Science Hackathon | Submissions data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions/15747 AIcrowd | Novartis Pharma Data Science Hackathon | Submissions #15747 data science hackathon novartis pharma aicrowd submissions https://www.aicrowd.com/challenges/novartis-pharma-data-science-hackathon/submissions/14652 AIcrowd | Novartis Pharma Data Science Hackathon | Submissions #14652 data science hackathon novartis pharma aicrowd submissions https://www.epo.org/fr/boards-of-appeal/decisions/t180031eu1 T 0031/18 (HIGH DRUG LOAD TABLET/Novartis AG, Novartis Pharma GmbH) du 26.11.2019 https://www.xing.com/profile/Margarita_Teplova Margarita Teplova - Senior Regional Representative - Alcon Pharma GmbH, a Novartis company | XING Margarita Teplova, Saratov Professional experience, contact details, portfolio, etc.: Find out more or get in touch with Margarita Teplova on XING. alcon pharma gmbh regional representative https://www.vidal.fr/medicaments/gammes/alpelisib-novartis-pharma-117466.html ALPELISIB NOVARTIS PHARMA alpelisib novartis pharma https://www.marketscreener.com/news/swiss-pharma-novartis-mulls-options-to-reduce-us-drug-prices-ce7d58ded08af420 Swiss Pharma Novartis Mulls Options to Reduce US Drug Prices | MarketScreener Sep 21, 2025 - Novartis is considering price-cutting options to present to US President Donald Trump by the end of September, Bloomberg News reported Sept. 20, citing a... swiss pharma drug prices novartis options https://www.novartis.com/news/media-releases/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19-solve-healthcare-challenges Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to... https://www.fiercebiotech.com/biotech/anji-pharma-secures-70m-series-b-for-phase-3-diabetes-asset-mid-stage-constipation Anji Pharma nabs $70M for late-stage diabetes treatment, ex-Novartis asset | Fierce Biotech Sep 28, 2021 - Anji Pharma wants to bring a Type 2 diabetes and chronic kidney disease treatment along with a constipation drug to market, and now the biotech has https://www.businesstoday.in/markets/stocks/story/pharma-major-dr-reddys-in-race-to-acquire-stake-in-novartis-india-arm-417915-2024-02-17 Pharma major Dr Reddy's in race to acquire stake in Novartis' India arm? - BusinessToday Feb 17, 2024 - The report comes a day after Novartis AG announced a strategic review of its India arm. The strategic review, the firm, said includes an assessment of the... https://www.fiercebiotech.com/biotech/big-pharma-rivals-pfizer-and-novartis-team-up-nash-combo-targets Big Pharma rivals Pfizer and Novartis team up on NASH combo targets | Fierce Biotech Oct 29, 2018 - Pfizer is joining forces with Novartis with a throw it all at the wall and see what sticks approach as they look to combine NASH assets to see if it can beat... https://www.arabnews.com/node/1490481/corporate-news Novartis, Sudair Pharma to produce cancer drugs in KSA | Arab News Apr 30, 2019 - Novartis International AG and Sudair Pharmaceuticals Company (Sudair Pharma) have signed a memorandum of understanding to collaborate on local manufacturing of... cancer drugs novartis sudair pharma produce https://www.epo.org/de/boards-of-appeal/decisions/t241365eu1 T 1365/24 (TABLETS COMPRISING ELTROMBOPAG OLAMINE/Novartis Pharma AG) vom 05.06.2025 https://www.bluewin.ch/en/news/novartis-raises-forecast-again-after-strong-start-to-the-year-2673115.html Pharma: Novartis raises forecast again after strong start to the year | blue News Novartis has continued the strong pace of growth of recent quarters in the first three months of 2025. Contrary to the expectations of many analysts, the... https://www.finanznachrichten.de/nachrichten-2026-03/68067223-novartis-pharma-ag-novartis-igan-data-in-new-england-journal-of-medicine-show-fabhalta-slowed-kidney-function-decline-by-49-3-399.htm Novartis Pharma AG: Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed... Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of...